Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M.
Envada had announced a $130M Series C funding in November 2024.
The company intends to use the funds to expand its clinical pipeline further in 2025, enhance its AI-driven discovery capabilities, and drug development efforts.
Led by Viswa Colluru, Ph.D., Founder and CEO, Enveda is a biotechnology company dedicated to creating new medicines using AI-powered tools to identify and characterize a wide range of molecules produced by living organisms, creating a database of chemical biodiversity. By growing, organizing, translating, and searching this library, Enveda learns from life’s evolved solutions to address new medical needs.
The company recently advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, to clinical trials. ENV-294 can fill a major gap in the immunology and inflammation (I & I) therapeutic area by potentially providing a safe and effective oral therapy.
FinSMEs
27/02/2025